105,091 Shares in Boston Scientific Corporation $BSX Acquired by First Nebraska Trust Co

First Nebraska Trust Co acquired a new stake in Boston Scientific Corporation (NYSE:BSX) in the first quarter, Holdings Channel.com reports. The firm acquired 105,091 shares of the medical equipment provider’s stock, valued at approximately $6,594,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of BSX. Renaissance Group LLC purchased a new position in Boston Scientific during the fourth quarter valued at approximately $28,064,000. Rathbones Group PLC increased its holdings in Boston Scientific by 20.9% during the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock worth $263,133,000 after acquiring an additional 477,680 shares during the period. Meiji Yasuda America Inc purchased a new stake in Boston Scientific in the 4th quarter worth approximately $4,708,000. Harvest Portfolios Group Inc. boosted its holdings in Boston Scientific by 6.1% in the 4th quarter. Harvest Portfolios Group Inc. now owns 597,341 shares of the medical equipment provider’s stock valued at $56,956,000 after purchasing an additional 34,598 shares during the period. Finally, LBP AM SA boosted its holdings in Boston Scientific by 8.4% in the 4th quarter. LBP AM SA now owns 434,393 shares of the medical equipment provider’s stock valued at $41,419,000 after purchasing an additional 33,534 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In other news, Director Cheryl Pegus acquired 1,770 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Edward J. Ludwig acquired 3,580 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the transaction, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders bought 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on BSX. TD Cowen decreased their price target on shares of Boston Scientific from $61.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $60.00 price objective on shares of Boston Scientific in a research note on Thursday. Bank of America reduced their target price on Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, May 18th. BTIG Research decreased their target price on Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Evercore set a $65.00 price target on Boston Scientific in a report on Monday, July 6th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported second-quarter adjusted earnings of $0.86 per share and revenue of $5.44 billion, exceeding consensus estimates of $0.83 and $5.38 billion, respectively. Revenue increased 7.5% year over year, while management highlighted approximately 7% organic sales growth and a 15% increase in adjusted EPS. Boston Scientific Q2 earnings call highlights
• Positive Sentiment: Management’s multiyear restructuring plan is intended to improve efficiency and generate roughly $500 million in savings, supporting longer-term margins despite restructuring costs of up to $800 million. Reported workforce reductions are expected to affect operations in Ireland and Costa Rica. Boston Scientific restructuring cuts
• Positive Sentiment: Penumbra reported second-quarter revenue of $390.0 million, up 14.9% year over year, with thrombectomy revenue rising 12.5% and embolization and access revenue increasing 20.0%. The results provide supportive operating momentum for Boston Scientific’s pending acquisition of Penumbra, although PEN will not issue full-year guidance during the transaction. Penumbra second-quarter financial results
• Neutral Sentiment: Analyst sentiment remains broadly constructive but more cautious: UBS reaffirmed a Buy rating with a $74 target, while TD Cowen and Truist maintained Buy ratings despite lowering targets to $56 and $57. Argus reiterated a Hold rating, and BTIG reduced its expectations.
• Negative Sentiment: Boston Scientific lowered its full-year outlook because of headwinds affecting its electrophysiology and WATCHMAN portfolios. Analysts also cited a reset in expectations for these businesses, limiting the near-term upside from the earnings beat. Boston Scientific lowered full-year guidance
• Negative Sentiment: A recall involving the Rapid Refill Continuous Injection System adds a product and execution risk, while the restructuring will create near-term charges before expected savings are realized. Boston Scientific earnings, recall and restructuring

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $46.75 on Friday. The company’s fifty day moving average price is $46.13 and its 200-day moving average price is $62.26. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The firm has a market capitalization of $69.48 billion, a price-to-earnings ratio of 18.93, a PEG ratio of 0.96 and a beta of 0.58. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.36%. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the previous year, the firm posted $0.75 EPS. The firm’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a share buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.